Emerging Cellular Therapies for Glioblastoma Multiforme

被引：11

作者：

Choi, Paul J. ^{[1
]}

Tubbs, R. Shane ^{[2
]}

Oskouian, Rod J. ^{[3
]}

机构：

[1] Seattle Sci Fdn, Clin Anat, Seattle, WA 98122 USA

[2] Seattle Sci Fdn, Neurosurg, Seattle, WA USA

[3] Swedish Neurosci Inst, Neurosurg, Seattle, WA USA

来源：

CUREUS | 2018年 / 10卷 / 03期

关键词：

glioblastoma multiforme; cellular therapy; temozolomide; molecular envelope technology; cellular vehicle; oncolytic virus;

D O I：

10.7759/cureus.2305

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Glioblastoma multiforme (GBM) is the most common type of malignant primary brain cancer in adults. It is composed of highly malignant cells that display metastatic and angiogenic characteristics, making it resistant to current first-line chemotherapy with temozolomide, an alkylating agent. Despite many years of research, GBM remains poorly responsive to multiple available therapies, giving GBM patients, who receive the conventional combination of chemoradiotherapies and surgical resection, a dismal prognosis. There is growing evidence that the conventional systemic chemotherapeutic agents for GBM are ineffective in improving the disease progression. We aim to explore the emerging cellular therapies which may play a significant role in treating GBM.

引用

页数：3

共 11 条

[1]

[Anonymous], 2007, MOL ENVELOPE TECHNOL

[2] Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review [J].